

Nadofaragene Firadenovec and Oportuzumab Monatox for BCG-Unresponsive, Non-Muscle Invasive Bladder Cancer: Effectiveness and Value

Key Stakeholder Organizations

ICER receives input on its reviews from patients and their families, patient advocacy organizations, clinicians, clinical societies, insurers, and drugmakers. We invite the public to submit recommendations for key stakeholders in any of these categories. The following is a list of organizations from which ICER has requested input as well as those that have provided public comments during the review. None of these individuals or organizations is responsible for the final content of ICER's report, and it should not be assumed that they support any part of the report, which is solely the work of the ICER team and its affiliated researchers.

For a complete list of key dates and opportunities for input on this project, please visit [ICER's website](#).

- American Society of Clinical Oncology
- Bladder Cancer Advocacy Network
- Cancer Support Community
- Community Oncology Alliance
- FerGene Inc.
- Harvard Pilgrim Health Care
- IPD Analytics
- Merck & Co., Inc.
- Premera Blue Cross
- Sesen Bio
- Society of Urologic Oncology